



28 August 2025

dorsaVi appoints Mathew Regan as Group Chief Executive Officer

Strengthening leadership to accelerate RRAM Innovation, Advanced Robotics Reflex Platform Development and drive global expansion

Key Highlights:

- **Mathew Regan appointed Group Chief Executive Officer, effective 1 November 2025.**
- **Former CEO of Artrya Limited (ASX: AYA), where he successfully reshaped the company's point of care AI-driven clinical platform and secured FDA clearances.**
- **Brings extensive multi-disciplinary expertise spanning digital health, AI, advanced manufacturing, and technology commercialisation, with a track record in scaling emerging technologies into global platforms.**
- **Mr Regan's appointment comes at a pivotal time for dorsaVi as the Company advances towards commercialising next-generation RRAM powered AI, Sensors and Robotics Technologies.**
- **Andrew Ronchi will remain the CEO of dorsaVi's sensor division, focused on driving U.S. sales and advancing commercial partnerships.**

Melbourne, Australia, 28 August 2025: dorsaVi (ASX:DVL) (dorsaVi or the Company) is pleased to announce that it has appointed Mathew Regan as Group Chief Executive Officer, effective 1 November 2025.

Mr Regan is an accomplished executive with a proven track record in transforming emerging technologies into globally scalable platforms. Having held senior leadership roles across ASX listed companies, including Artrya Limited (ASX:AYA) and Imdex (ASX: IMD), positioning him robustly to lead dorsaVi's next phase of growth.

In his most recent role at Artrya, Mr Regan successfully repositioned the company's AI driven clinical imaging platform, secured FDA clearances and enabled adoption by hospitals and clinicians globally. Widely recognised for his ability to translate vision into delivery, Mr Regan

brings broad experience across digital health, artificial intelligence, advanced manufacturing, and IT infrastructure.

Driving the Next Phase of Growth

Mr Regan's appointment comes at a pivotal time for dorsaVi as the Company advances the commercialisation of its next-generation RRAM-enabled sensor architecture and explores broader applications through its Reflex platform¹. These innovations underpin dorsaVi's strategy to expand beyond traditional clinical and workplace monitoring into high-growth verticals such as robotics, neuromorphic computing, and edge AI.

With internal testing already demonstrating breakthrough reductions in latency and power consumption for biomedical sensing applications², dorsaVi is well-positioned to leverage RRAM-enabled capabilities across multiple industries. The ongoing evaluation of the Reflex platform for next-generation robotics and human-machine interfaces mark a significant step toward enabling sub-millisecond reactions and in-sensor decision-making for autonomous systems, collaborative robots, and advanced wearables.

In parallel, the recent launch of Artemis Labs³, dorsaVi's dedicated innovation subsidiary, provides a unified platform to accelerate the development of RRAM-enabled sensor systems, edge AI models, and robotic reflex applications. Artemis Labs consolidates dorsaVi's core IP with its exclusive RRAM license and will act as the Company's engine for developing next-generation human-machine interface technologies.

Mr Regan's track record in scaling emerging technologies into global platforms makes him uniquely positioned to accelerate these initiatives, secure strategic partnerships, and unlock new commercial opportunities in both existing and adjacent markets.

Gernot Abl, Chairman of dorsaVi, said:

"We are delighted to welcome Mat as Group CEO at such an exciting time for dorsaVi. His proven ability to transform technology-driven businesses and unlock commercial value makes him uniquely suited to lead our next phase of growth. With our recent licensing of cutting-edge RRAM technology and expanding focus on robotics, neuromorphic computing, and edge AI, dorsaVi is entering high-growth global markets. Mathew's leadership will be instrumental in realising the full commercial potential of our platform across multiple industries."

Mathew Regan said:

"I'm excited to be joining dorsaVi as Group CEO. Gernot, Andrew, and the Board have built a strong foundation, and I look forward to working with them to help scale the business globally. A key attraction for me was the Company's strategic collaborations in RRAM and the commercial potential of its next-generation sensor technologies. I'm energised by the opportunity to lead a team focused on delivering innovation into new and emerging markets."

¹ Refer to ASX announcement dated 04 August 2025

² Refer to ASX announcement dated 22 July 2025

³ Refer to ASX announcement dated 20 August 2025

Sensor Business Focus

Andrew Ronchi will continue as CEO of dorsaVi's sensor division, focusing on:

- Scaling adoption of the Company's FDA-cleared movement analytics platform
- Driving U.S. commercial growth and strategic partnerships
- Supporting integration of next-generation RRAM-enabled capabilities

This dual-leadership model allows dorsaVi to drive innovation through new technology platforms while maintaining focus on scaling its existing commercial business globally.

Details of Mr Regan's remuneration package are included in Appendix 1.

This release has been authorised for lodgement by the Company's Board of Directors.

- ENDS -

For further information about dorsaVi, please contact:

Gernot Abl

Chairman

+61 419 802 653

Email: ga@dorsaVi.com

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Boeing, Monash Health, Coles, Woolworths, Toll, Toyota, Orora, Mineral Resources and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove+) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refer to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsaVi.com

Appendix 1 - Material Terms of Mr Mathew Regan's Employment Agreement

Item	Description
Commencement Date	1 November 2025
Term	No fixed term
Fixed Remuneration	\$300,000pa total fixed remuneration exclusive of statutory superannuation.
Long-Term Incentive (LTI) (100% at risk)	<p>The following Performance Rights will be issued to Mathew Regan or his Nominee for nil cash consideration as follows:</p> <p>Tranche 1 - 8,000,000 Performance Rights with a vesting condition of the Company achieving a \$0.10 VWAP of Shares over the previous 15 trading days within 24 months of the issue date.</p> <p>Tranche 2 - 8,000,000 Performance Rights with a vesting condition of the Company achieving a \$0.15 VWAP of Shares over the previous 15 trading days within 30 months of the issue date.</p> <p>Tranche 3 - 8,000,000 Performance Rights with a vesting condition of the Company achieving a \$0.20 VWAP of Shares over the previous 15 trading days within 36 months of the issue date.</p> <p>The issue of the Performance Rights will be subject to Shareholder approval at the Company's next General Meeting of Shareholders.</p> <p>The recipient must be employed by the Company 12 months following the issue date in order for the Performance Rights to vest.</p>
Termination	<p>Either party may terminate the Executive Contract with 3 months' written notice. Mr Regan may be required to serve out all or part of this period or be paid in lieu of notice at the Board's election.</p> <p>The Company may immediately terminate the Employment Agreement without notice in certain circumstances.</p>